Loading
A phase 1/2 trial of Durvalumab, Capivasertib, Oleclumab, Trastuzumab deruxtecan and Datopotamab deruxtecan in triple-negative breast cancer, run by AstraZeneca, active and no longer recruiting.
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer is a phase 1/2 interventional study registered as NCT03742102 by AstraZeneca, with 243 participants enrolled, started 2018-12-21 and due to reach its primary completion in 2024-11-29. Interventions recorded: Durvalumab, Capivasertib, Oleclumab, Paclitaxel, Trastuzumab deruxtecan and Datopotamab deruxtecan. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
243 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2026-02-02), not from a publication
Source95% CI 13.0 to NA; Figures from the ClinicalTrials.gov results section (first posted 2026-02-02), not from a publication · 95% CI 12.9 to 40.0 · 95% CI 18.6 to 31.9 · 95% CI 18.8 to NA · NA - Not calculable due to insufficient number of events for upper limit of confidence interval · NA - Not calculable due to insufficient number of events for upper limit of confidence interval
Source95% CI 5.4 to 11.3; Figures from the ClinicalTrials.gov results section (first posted 2026-02-02), not from a publication · 95% CI 5.4 to 10.3 · 95% CI 4.8 to 9.3 · 95% CI 8.4 to 16.3 · 95% CI 11.0 to 21.1 · 95% CI 6.9 to 13.8
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Dose Limiting Toxicity (DLT) Eventsprimary | Arm 2 | 6 | 0 participants | - | - | link |
| Arm 5 | 6 | 0 participants | ||||
| Arm 6 | 6 | 0 participants | ||||
| Arm 7 | 6 | 0 participants | ||||
| Overall Survival (Duration) | Arm 1 | 23 | 30 months | - | - | link |
| Arm 2 | 31 | 32.6 months | ||||
| Arm 5 | 33 | 24.8 months | ||||
| Arm 6 | 58 | 30.3 months | ||||
| Arm 7 | 62 | NA - Not calculable due to insufficient number of events for upper limit of confidence interval | ||||
| Arm 8 | 33 | NA - Not calculable due to insufficient number of events for upper limit of confidence interval | ||||
| Progression-free Survival (PFS) | Arm 1 | 23 | 7.3 months | - | - | link |
| Arm 2 | 31 | 6.4 months | ||||
| Arm 5 | 33 | 8.3 months | ||||
| Arm 6 | 58 | 12.6 months | ||||
| Arm 7 | 62 | 14 months | ||||
| Arm 8 | 33 | 11.2 months |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Datopotamab deruxtecan, Durvalumab, Triple-negative breast cancer trials open today (registry snapshot and UK sites), AstraZeneca and the tag pipeline.
Shares Datopotamab deruxtecan, Metastatic triple-negative breast cancer, AstraZeneca, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Capivasertib, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), AstraZeneca and the tag pipeline.
Shares Datopotamab deruxtecan, Durvalumab, AstraZeneca, Immune checkpoint inhibitors and the tag pipeline.
Shares Trastuzumab deruxtecan, Durvalumab, AstraZeneca, Immune checkpoint inhibitors and the tag pipeline.
Shares Durvalumab, AstraZeneca, Immune checkpoint inhibitors and the tag pipeline.
Shares Durvalumab, AstraZeneca, Immune checkpoint inhibitors and the tag pipeline.
Shares Durvalumab, AstraZeneca, Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/